| Literature DB >> 18937826 |
Märit Pringle1, Christer Bergsten, Lise-Lotte Fernström, Helena Höök, Karl-Erik Johansson.
Abstract
BACKGROUND: Digital dermatitis in cattle is an emerging infectious disease. Ulcerative lesions are typically located on the plantar skin between the heel bulbs and adjacent to the coronet. Spirochetes of the genus Treponema are found in high numbers in the lesions and are likely to be involved in the pathogenesis. The aim of this study was to obtain pure cultures of spirochetes from cattle with digital dermatitis and to describe them further.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18937826 PMCID: PMC2576277 DOI: 10.1186/1751-0147-50-40
Source DB: PubMed Journal: Acta Vet Scand ISSN: 0044-605X Impact factor: 1.695
Origin of the Treponema sp. isolates from Swedish cattle.
| Isolate | Animal origin | County code | Year of isolation | Comment |
| V1 | herd A | O | 2005 | about 20% clinical DD |
| T 413 | herd B | C | 2006 | sporadic cases of DD in the herd |
| T 551 | challenge studya | O | 2006 | isolated 25 days post infection |
| T 551B | challenge studya | O | 2006 | isolated 41 days post infection |
| T 603 | herd C | C | 2006 | sporadic cases of DD in the herd |
| T 657 | herd C | C | 2006 | sporadic cases of DD in the herd |
| T 2378 | herd D | O | 2005 | sporadic cases of DD in the herd |
a unpublished, see discussion.
MIC of six antimicrobial substances for two control strains from two tests under identical conditions as for the Treponema sp. isolates.
| Strain | Days of incubation | MIC (μg/ml) | |||||
| Tiamulin | Valnemulin | Tylosin | Aivlosin | Lincomycin | Doxycycline | ||
| 4 and 7 | >1 | 0.25–0.5 | 2 | 4 | 1–2 | 0.5 | |
| 7 and 11 | 0.125 | 0.063 | 8–16 | 1–2 | 0.5–1 | 0.25 | |
a Approved quality control ranges by the CLSI for susceptibility tests performed by micro dilution in Mueller Hinton broth [25,26].
b Proposed quality-control ranges by Pringle et al. for susceptibility tests performed in brain heart infusion broth with 10% fetal calf serum [24].
MIC of six antimicrobial substances for one Treponema sp. isolate (V1) in nine subsequent susceptibility tests.
| Days of incubation | MIC (μg/ml) | |||||
| Tiamulin | Valnemulin | Tylosin | Aivlosin | Lincomycin | Doxycycline | |
| 8 | 0.5 | 0.125 | ≤0.5 | ≤0.25 | >4 | 0.063 |
| 6a | 0.5 | 0.125 | ≤0.5 | ≤0.25 | >4 | 0.031 |
| 9a | 1 | 0.125 | ≤0.5 | ≤0.25 | >4 | 0.063 |
| 7 | 0.5 | 0.125 | ≤0.5 | ≤0.25 | >4 | 0.063 |
| 10 | 0.5 | 0.063 | ≤0.5 | ≤0.25 | >4 | 0.063 |
| 4a | 0.5 | 0.063 | ≤0.5 | ≤0.25 | >4 | 0.063 |
| 7a | 0.5 | 0.125 | ≤0.5 | ≤0.25 | >4 | 0.063 |
| 7 | 0.5 | 0.125 | ≤0.5 | ≤0.25 | >4 | 0.031 |
| 11 | 0.5 | 0.063 | ≤0.5 | ≤0.25 | >4 | 0.063 |
| 5 | 0.5 | 0.125 | ≤0.5 | ≤0.25 | >4 | 0.063 |
| 9 | 0.5 | 0.125 | ≤0.5 | ≤0.25 | >4 | 0.063 |
a The same test was read twice with three days interval.
MIC of six antimicrobial substances for seven Treponema sp. isolates.
| Isolate | No. of tests performed | MIC (μg/ml) | |||||
| Tiamulin | Valnemulin | Tylosin | Aivlosin | Lincomycin | Doxycycline | ||
| V1 | 9 | 0.5–1 | 0.063–0.125 | ≤0.5 | ≤0.25 | >4 | 0.031–0.063 |
| T 413 | 5 | 0.5–1 | 0.125 | ≤0.5 | ≤0.25 | ≥4 | 0.063 |
| T 551 | 4 | 0.25–0.5 | 0.063–0.125 | ≤0.5 | ≤0.25 | >4 | 0.031–0.125 |
| T 551B | 3 | 0.5 | 0.125–0.25 | ≤0.5 | ≤0.25 | >4 | 0.063 |
| T 603 | 2 | 0.5–1 | 0.125–0.25 | ≤0.5 | ≤0.25 | >4 | 0.125 |
| T 657 | 3 | 0.5 | 0.063–0.125 | ≤0.5 | ≤0.25 | >4 | 0.125–0.25 |
| T 2378 | 5 | 0.25–0.5 | 0.125 | ≤0.5 | ≤0.25 | >4 | 0.031–0.063 |
Enzymatic profile for seven Treponema sp. isolates determined by the API-ZYM system.
| Isolate | Enzyme activitya | ||||||||||||||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | |
| V1 | S | W | W | - | - | - | - | - | - | S | S | - | S | W | - | - | S | - | - |
| T 413 | S | W | W | - | - | - | - | - | - | S | S | - | S | S | - | - | S | - | - |
| T 551 | S | W | W | - | - | - | - | - | - | S | S | - | S | W | - | - | S | - | - |
| T 551B | S | W | W | - | W | - | - | - | - | S | W | - | S | W | - | - | S | - | - |
| T 603 | S | W | W | - | - | - | - | - | - | S | W | - | S | W | - | - | S | - | - |
| T 657 | S | W | W | - | - | - | - | - | - | S | W | - | S | W | - | - | S | - | - |
| T 2378 | S | W | W | - | - | - | - | - | - | S | W | - | S | W | - | - | S | - | - |
1 alkaline phosphatase; 2 C4 esterase; 3 C8 esterase lipase; 4 C14 lipase; 5 leucine arylamidase; 6 valine arylamidase; 7 cystine arylamidase; 8 trypsin; 9 α-chymotrypsin; 10 acid phosphatase; 11 naphtholphosphohydrolase; 12 α-galactosidase; 13 β-galactosidase; 14 β-glucuronidase; 15 α-glucosidase; 16 β-glucosidase; 17 N-acetyl-β-glucosaminidase; 18 α-mannosidase; 19 α-fucosidase.
a S, strong; W, weak; -, negative.
Figure 1Pulsed-field gel electrophoresis patterns for seven Lane 1, Lambda Ladder PFG Marker (New England BioLabs); lane 2, V1; lane 3, T 413; lane 4, T 551; lane 5, T551B; lane 6, T 603; lane 7, T 657; lane 8, T 2378.
Figure 2Random amplified polymorphic DNA banding patterns for seven Lane 1, DNA Molecular Weight Marker VI (Roche Applied Science); lane 2, V1; lane 3, T 413; lane 4, T 551; lane 5, T551B; lane 6, T 603; lane 7, T 657; lane 8, T 2378.